MeSH tree: E05.478.550
Researchers led by Universitätsmedizin Frankfurt and Goethe University Frankfurt have identified how particularly aggressive forms of lymphoma can be recognized. By combining genetic and proteomic analyses, the scientists ...
Jul 3, 2026
0
3
Every state, along with Washington, D.C., requires children to obtain certain vaccinations before they can attend school or childcare These mandates date back decades, and many public health experts consider them a foundational ...
Jun 29, 2026
0
4
Researchers at Weill Cornell Medicine, Cedars-Sinai Medical Center and Roswell Park Comprehensive Cancer Center have developed genetically engineered CAR T cells that specifically target and kill bladder cancer cells. The ...
Jun 26, 2026
0
5
Leading CAR T cell therapy researchers have developed a human-in-the-loop artificial intelligence (AI) framework that centers scientists' expertise to find viable target antigens for CAR T cell therapy. The work was led by ...
Jun 25, 2026
0
9
Amid a worsening flu outbreak at Lackland Air Force Base in San Antonio, Texas, the U.S. Air Force, Army and Navy are once again requiring new recruits to get vaccinated against the influenza virus, according to ABC News. ...
Jun 25, 2026
0
3
Hepatitis B (HBV) and hepatitis C (HCV) are viral infections that can lead to health conditions such as cirrhosis, cancer and death if unmanaged. HBV can be transmitted through sexual contact, blood exposure and mother-to-child ...
Jun 25, 2026
0
2
Researchers at the Icahn School of Medicine at Mount Sinai have found that wearable devices may help clinicians detect cytokine release syndrome (CRS)—a common and potentially serious side effect of CAR-T cell therapy—hours ...
Jun 22, 2026
0
5
Early results from a UCL- and UCLH-led clinical trial suggest that a type of CAR T-cell therapy—developed by Autolus Therapeutics, a UCL spinout—could offer a new treatment approach for people with severe, treatment-resistant ...
Jun 15, 2026
0
10
Researchers at the University of Maryland School of Medicine (UMSOM) have identified a target that may improve the response to CAR T-cell therapy, a treatment for patients with recurrent or difficult-to-treat blood cancers.
Jun 15, 2026
0
3
Dual-target CAR T-cell therapy for recurrent glioblastoma (GBM), delivered directly into the cerebrospinal fluid (CSF), triggers a broad immune response, with natural killer (NK) cell activation linked to better patient outcomes ...
Jun 15, 2026
0
3
